1
) and the third leading cause of cancer death in women 2 • Despite treatment for earlier-stage disease and adjuvant systemic therapy, ≈ 30% to 50% of women with an initial early-stage BC diagnosis will develop recurrent advanced BC (aBC) or metastatic BC (mBC) [3] [4] [5] • Median overall survival after recurrence of BC is 2 to 3 years, 2 with only 23% of patients with mBC surviving 5 years 6 • Current goals of mBC therapy are to ameliorate symptoms, delay disease progression, improve or at least maintain quality of life, and prolong overall survival; however, the majority of BC-related deaths are a result of complications from recurrent or metastatic disease 3 • A recent retrospective analysis of linked Surveillance, Epidemiology, and End Results Program-Medicare data revealed significantly higher rates of resource utilization and healthcare costs in women with stage IV estrogen receptor-positive (ER+) BC who did not receive human epidermal growth factor receptor 2 (HER2)-targeted therapy compared with women without cancer 7 • Limited published data are available on the resource use and costs associated with treating hormone receptor-positive (HR+)/HER2-negative (HER2−) aBC [7] [8] [9] 
OBJECTIVE
• To conduct a structured review of the literature reporting how various treatments affect the economic burden associated with treating postmenopausal women with HR+/HER2− aBC
METHODS
Data Sources Literature Selection 
RESULTS

Economic Burden
• Nine studies related to the economic burden of aBC were identified in the literature review -The 6 studies reporting actual costs are presented in Table 2 • The direct and indirect economic costs attributable to aBC were substantial, and the cost burden increased with disease stage 10, 11 • Early recurrence was associated with a higher cost burden.
Fisher et al. 
Direct costs associated with mBC
• The majority of direct health expenditures were due to hospital services, pharmacy costs, and special equipment 10 • One study found that the overall cost of hospital care was the most common economic burden 12 -Cost of hospital care was specifically associated with CT treatment
• A separate study from the records of 14 US health plans found hospital outpatient costs to be among the most common economic burdens, with a mean annual cost of $119,211 13 • For late-stage BC, the main direct costs were cytotoxic treatments and hormone therapy 14 • Inpatient hospital care was a significant cost driver for women with mBC compared with women without cancer (P < .001) 7 Indirect costs associated with mBC
• Indirect costs have been recognized as an important component in evaluating the economic burden of mBC 15 • Women with mBC experience significantly higher productivity loss due to paid time off and short-term disability compared with women with early-stage BC 15 • The economic burden associated with productivity loss is also significant for caregivers 15 • Supportive care represented another substantial indirect cost 
Economic Evaluations
• Thirteen economic evaluations were identified in the literature review
• One study reviewed the cost-effectiveness of fulvestrant monotherapy vs fulvestrant plus other standard treatments
• Seven studies reviewed the cost-effectiveness of everolimus plus exemestane -These studies were conducted in Greece, Russia, the United Kingdom, and the United States
• Two studies evaluated the budget impact of everolimus plus exemestane
• Three systematic reviews compared cost-effectiveness across multiple nonsteroidal AIs (NSAIs)
-These studies were conducted in the United Kingdom and the United States
Fulvestrant
• Results from the CONFIRM study found fulvestrant monotherapy to be cost-effective compared with fulvestrant plus other standard treatments available in Mexico 16 Everolimus plus exemestane
• Cost-effectiveness evaluations -5 of 7 studies found that everolimus plus exemestane was more cost-effective vs exemestane monotherapy or other NSAIs [17] [18] [19] [20] [21] • These studies were conducted in Greece, Russia, the United Kingdom, and the United States -2 of 7 studies reported that everolimus plus exemestane was not a cost-effective treatment from a payer perspective compared with exemestane monotherapy (in the United States) or exemestane plus placebo (in the United Kingdom) 22, 23 • Budget impact evaluations -Everolimus plus exemestane treatment did not change overall cost in Egypt 24 • Everolimus plus exemestane acquisition costs were expected to be offset by fewer patients progressing and fewer adverse events compared with paclitaxel and capecitabine-docetaxel regimens -Another budget impact study found that everolimus plus exemestane (after letrozole or anastrozole failure) had a minimal impact on overall United States healthcare costs 25 • Increased pharmacy costs were noted, but these were expected to be offset by reduced medical services costs
Multiple NSAIs
• Overall, from a third-party payer perspective, AIs administered as first-line and second-line treatments were reported to be highly cost-effective vs tamoxifen or other older treatments, irrespective of country 26, 27 • In a systematic review conducted in the United Kingdom, treatment with any NSAI monotherapy was compared with CT, and NSAIs were found to be more cost-effective from a payer perspective 28 -A cost-effectiveness analysis noted that utility values for NSAI treatment and CT treatment were 0.55 to 0.75 and 0.51 to 0.60, respectively
• A cost-effectiveness model from a systematic review conducted in the United States comparing overall costs across treatments found an average lifetime cost of $110,000 29 -NSAI treatment was more cost-effective than taxanes or tamoxifen, irrespective of line of therapy, from a payer perspective
CONCLUSIONS
• Patients with aBC had increased economic burden vs patients with milder forms of the disease • The majority of the economic evaluation studies identified in this literature review examined the cost-effectiveness of everolimus plus exemestane (7/13 studies) • Among these studies, over 70% (5/7) found everolimus plus exemestane to be more cost-effective vs exemestane monotherapy or other NSAIs • Furthermore, in the 2 budget-impact evaluation studies identified, everolimus plus exemestane treatment was found to have minimal or no impact on overall healthcare costs, as the cost of this combination treatment was expected to be offset by other factors (eg, reduced number of progressed patients and reduced medical services costs) • NSAIs were found to be more cost-effective than taxanes, tamoxifen, CT, or other older treatments • Treatments that reduce risk of relapse and have manageable safety profiles may help reduce the economic burden associated with aBC
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